| Name | Title | Contact Details |
|---|
Chesapeake IRB and its Canadian affiliate, IRB Services, have been in business since 1993. They have established a reputation for excellence that is based on quality work, efficient processes, and excellent customer service. Chesapeake IRB`s schedule of 5 weekly meetings, daily expedited review capability, 4 day turnaround for protocols and 24-hour turnaround for Principal Investigators (PIs) has helped our clients become more competitive for industry sponsored studies; including Phase I research. While the majority of our studies are biomedical or device related, we have a broad range of social/behavioral studies that are often government or foundation funded. We work with you as a risk mitigation partner to meet your needs.
Medocity is a leading healthcare tech and services company specializing in digital care solutions to deliver optimized, continuous care between visits.
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) is a global organization dedicated to advancing military medicine. We serve military, medical, academic and government clients by administering, managing and supporting preeminent scientific programs that benefit members of the armed forces and civilians alike.
Global Health Systems Inc is a Aliso Viejo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.